Antares Pharma, Inc. (Amex: AIS) today announced that it will release its third quarter 2009 financial results after the market closes on Monday, November 9, 2009, and host a conference call shortly thereafter at 4:30 PM (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, Executive Vice President and Chief Financial Officer, will host the call.

Interested parties may participate in the conference call by dialing 1-800-762-8908 (US), or 480-629-9774 (International), 5-10 minutes prior to the start of the call. A replay of the conference call will be available approximately 2 hours after the call's conclusion through 12:00 PM Eastern Time on November 23, 2009 by dialing 800-406-7325 (US), or 303-590-3030 (International), and entering reservation #4181042. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares website at www.antarespharma.com.

About Antares Pharma (www.antarespharma.com)

Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products. The company’s subcutaneous injection technology platforms include VibexTM disposable pressure-assisted auto injectors, ValeoTM/Vision® reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, Antares Pharma has a multi-product deal with Teva Pharmaceuticals Industries, Ltd that includes Tev-Tropin® human growth hormone and a partnership with Ferring Pharmaceuticals. In the gel-based area, the company’s lead product candidate, Anturol™, an oxybutynin ATD™ gel for the treatment of OAB (overactive bladder), is currently under evaluation in a pivotal Phase 3 trial. Antares also has a partnership with BioSante that includes LibiGel® (transdermal testosterone gel) in Phase III clinical development for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and currently marketed in the U.S. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.